The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease Pathology
Open accessAbstract
Alzheimer's disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer's disease are expected to triple over the next 50 years. Consequently, the development of treatments that slow or halt the disease progression have become imperative to both improve the quality of life for patients and reduce the health care costs attributable to Alzheimer's disease. Here, we demonstrate that the active component of marijuana, Delta9-tetrahydrocannabinol (THC), competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid beta-peptide (Abeta) aggregation, the key pathological marker of Alzheimer's disease. Computational modeling of the THC-AChE interaction revealed that THC binds in the peripheral anionic site of AChE, the critical region involved in amyloidgenesis. Compared to currently approved drugs prescribed for the treatment of Alzheimer's disease, THC is a considerably superior inhibitor of Abeta aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
Levine, H. (1993) · Protein Science · doi:10.1002/pro.5560020312 · Cited by 2,264
Inestrosa, N. C., Alvarez, A., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,101
Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & de Ceballos, M. L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4540-04.2005 · Cited by 785
Clinical spectrum of CADASIL: a study of 7 families
Chabriat, H., Vahedi, K., Bousser, M. G., Iba-Zizen, M. T., Joutel, A., Nibbio, A., Nagy, T. G., Tournier Lasserve, E., Krebs, M. O., Julien, J., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91557-5 · Cited by 669
Benito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., & Romero, J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11136.2003 · Cited by 624
β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies
Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 568
Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361
Estimated Prevalence of Alzheimer's Disease in the United States
Evans, D. A. (1990) · The Milbank Quarterly · doi:10.2307/3350099 · Cited by 357
Ritchie, K., & Kildea, D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91556-7 · Cited by 340
Johnson, G., & Moore, S. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775193127 · Cited by 321
Alvarez, A., Alarcón, R., Opazo, C., Campos, E. O., Muñoz, F. J., Calderón, F. H., Dajas, F., Gentry, M. K., Doctor, B. P., De Mello, F. G., et al. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03213.1998 · Cited by 317
Acetylcholinesterase inhibitors: novel activities of old molecules
RACCHI, M. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.027 · Cited by 288
Piazzi, L., Rampa, A., Bisi, A., Gobbi, S., Belluti, F., Cavalli, A., Bartolini, M., Andrisano, V., Valenti, P., & Recanatini, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0340602 · Cited by 266
Rozemuller, J. M., Eikelenboom, P., Stam, F. C., Beyreuther, K., & Masters, C. L. (1989) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198911000-00009 · Cited by 243
Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide
Milton, N. G. N. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00936-9 · Cited by 125
The good and the bad effects of (−) trans-delta-9-tetrahydrocannabinol (Δ9-THC) on humans
Carlini, E. A. (2004) · Toxicon · doi:10.1016/j.toxicon.2004.05.009 · Cited by 108
Szegletes, T., Mallender, W. D., & Rosenberry, T. L. (1998) · Biochemistry · doi:10.1021/bi972158a · Cited by 96
A credit-card library approach for disrupting protein–protein interactions
Xu, Y., Shi, J., Yamamoto, N., Moss, J. A., Vogt, P. K., & Janda, K. D. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.11.052 · Cited by 93
Self-citationMedicinal chemistry approaches for the treatment and prevention of Alzheimer's disease
Бачурин, С. О. (2002) · Medicinal Research Reviews · doi:10.1002/med.10026 · Cited by 92
Belluti, F., Rampa, A., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Cavalli, A., Recanatini, M., & Valenti, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049515h · Cited by 87
Role of the endocannabinoid system in Alzheimer's disease: New perspectives
Pazos, M. R., Núñez, E., Benito, C., Tolón, R. M., & Romero, J. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.03.026 · Cited by 75
Dickerson, T. J., Beuscher, Rogers, C. J., Hixon, M. S., Yamamoto, N., Xu, Y. Y., Olson, A. J., & Janda, K. D. (2005) · Biochemistry · doi:10.1021/bi051613x · Cited by 40
Self-citationEvaluation of “Credit Card” Libraries for Inhibition of HIV-1 gp41 Fusogenic Core Formation
Xu, Y. Y., Lü, H., Kennedy, J. P., Yan, X., McAllister, L. A., Yamamoto, N., Moss, J. A., Boldt, G. E., Jiang, S., & Janda, K. D. (2006) · Journal of Combinatorial Chemistry · doi:10.1021/cc0600167 · Cited by 33
Self-citation(1998) · doi:10.1002/(sici)1096-987x(19981115)19:14<1639::aid-jcc10>3.0.co;2-b
Cited by
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
History of Cannabis and Its Preparations in Saga, Science, and Sobriquet
Russo, E. B. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790144 · Cited by 621
Aizpurua-Olaizola, O., Soydaner, U., Öztürk, E., Schibano, D., Simsir, Y., Navarro, P., Etxebarria, N., & Usobiaga, A. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00949 · Cited by 467
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
Pharmacology of Medical Cannabis
Amin, M. R., & Ali, D. W. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-21737-2_8 · Cited by 278
Metadata
- Authors
- Eubanks, L. M., Rogers, C. J., Beuscher, Koob, G. F., Olson, A. J., Dickerson, T. J., & Janda, K. D.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-08-09
- Volume
- 3
- Issue
- 6
- Pages
- 773-777
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2143209864
- Cited by
- 268
- References
- 28
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.